Cancer News and Research

Latest Cancer News and Research

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A.

From Baxter International Inc. 11 Dec 2013

Discovery could lead to new way to combat cancer

One way to defeat an opponent is to cut off its supply lines. Tumors are no different. The supply lines for tumors are the blood vessels that ferry oxygen and nutrients to the cells. Restricting the blood vessels that feed tumor cells can shrink the tumor. A cross-institutional international team of scientists recently discovered a new, important step of the process that grows new blood vessels, a discovery that could lead to a new way to combat cancer.

11 Dec 2013

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.

10 Dec 2013

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Indulgences abound during the holidays—from family gatherings to parties with friends and even stockings stuffed with goodies from Santa. For children with diabetes, overindulging on the delicacies of the season could result in more than a stomach ache, it could mean a trip to the emergency room.

10 Dec 2013

Pemetrexed, paclitaxel regimens equally effective in NSCLC

PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles.

10 Dec 2013

First Edition: December 10, 2103

Today's early morning highlights from the major news organizations, including reports about how health law advocates are developing new messaging strategies.

10 Dec 2013

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Foundation Medicine today announced new data from a pilot study demonstrating that its fully informative genomic profile for hematologic malignancies, FoundationOne Heme, identified both novel and previously reported clinically actionable genomic alterations in multiple myeloma cases. These data were presented in an oral presentation titled Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma (abstract number 755) by Alexander Lesokhin, M.D., medical oncologist, Memorial Sloan-Kettering Cancer Center, at the 55th American Society of Hematology Annual Meeting in New Orleans.

10 Dec 2013

Sanofi US launches second PiPH innovation challenge to improve drug development process

Today, Sanofi US launched its second Partners in Patient Health Innovation Challenge: Collaborate | Innovate, which will award $100,000 to the winning team. This year's theme is "Co-Creating for Breakthroughs: Moving toward a collaborative research and development ecosystem."

10 Dec 2013

Australian childhood cancer death rates drop significantly over decade

Australian childhood cancer death rates have dropped significantly over a decade, new Cancer Council Queensland research shows.

10 Dec 2013

Researchers explain why anti-tumor activity of specific immune cells suppress during tumor growth

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth.

10 Dec 2013

Scientists unveil novel piece of puzzle of cancer cell DNA repair mechanisms

Research with a Finnish background facilitates the development of more effective cancer medication. Cancer cells have an exceptional ability to repair damage to their DNA caused during uncontrolled cell division.

10 Dec 2013

COC launches first clinic on London's Harley Street for specialised cancer treatment

Care Oncology Clinic, an independent, private organisation providing oncology treatments, announces today the launch of its first clinic on London's Harley Street. Delivered by leading oncologists and palliative care doctors, the clinic is the first of its kind, specifically set up to offer a specialised cancer treatment by targeting the energy requirements of cancer cells using existing medicines that are already licensed for this purpose, have an acceptable safety profile and are low cost. Designed for patients for whom the standard oncology treatment regime is not available, viable, tolerable or providing benefit, this is a new option for treating these cancer patients.

10 Dec 2013

ACoS Commission on Cancer, PHCQA partner to make PA cancer quality data available to public

The American College of Surgeons Commission on Cancer has joined with the Pennsylvania Health Care Quality Alliance to make cancer quality data from participating Pennsylvania hospitals available to the public. The initiative, which is the first of its kind in the U.S., will include data from 72 percent (52 programs) of all CoC-accredited cancer programs in Pennsylvania.

10 Dec 2013

Article outlines new approach for reviewing potential downsides of screening recommendation

Screening to detect medical conditions has become standard practice for many diseases, but insufficient attention has been paid to the potential for harm, according to research conducted at the University of North Carolina.

10 Dec 2013

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

Researchers in the Women's Cancer Program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes.

10 Dec 2013

Scientists devise method to measure forces in 3D tissues, living embryos

As embryonic tissue develops, cells push and pull on each other, and they must do so correctly for the tissue to develop properly. Now scientists at Harvard University have devised the first method to measure these forces in three-dimensional (3D) tissues and living embryos.

10 Dec 2013

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.

10 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology.

10 Dec 2013

Cancer News and Research

Latest Cancer News and Research

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Discovery could lead to new way to combat cancer

Immunologists receive $4.8M grant to target multiple diseases by manipulating enzyme

Endocrinologist suggests parents to check their child's blood sugar more often during holidays

Pemetrexed, paclitaxel regimens equally effective in NSCLC

First Edition: December 10, 2103

FoundationOne Heme identifies clinically actionable genomic alterations in multiple myeloma cases

Sanofi US launches second PiPH innovation challenge to improve drug development process

Australian childhood cancer death rates drop significantly over decade

Researchers explain why anti-tumor activity of specific immune cells suppress during tumor growth

Scientists unveil novel piece of puzzle of cancer cell DNA repair mechanisms

COC launches first clinic on London's Harley Street for specialised cancer treatment

ACoS Commission on Cancer, PHCQA partner to make PA cancer quality data available to public

Article outlines new approach for reviewing potential downsides of screening recommendation

Researchers identify 10 genes that may signify trifecta of benefits for women with ovarian cancer

Scientists devise method to measure forces in 3D tissues, living embryos

Drugs that enhance oxidative stress kill rhabdomyosarcoma tumor cells

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in